Treace Medical Concepts, Inc.
TMCI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $209,357 | $187,118 | $141,838 | $94,419 |
| % Growth | 11.9% | 31.9% | 50.2% | – |
| Cost of Goods Sold | $41,093 | $35,181 | $27,523 | $16,888 |
| Gross Profit | $168,264 | $151,937 | $114,315 | $77,531 |
| % Margin | 80.4% | 81.2% | 80.6% | 82.1% |
| R&D Expenses | $20,589 | $15,440 | $13,584 | $10,204 |
| G&A Expenses | $55,720 | $47,031 | $32,999 | $18,432 |
| SG&A Expenses | $203,363 | $187,925 | $137,566 | $83,837 |
| Sales & Mktg Exp. | $147,643 | $140,894 | $104,567 | $65,405 |
| Other Operating Expenses | $0 | $0 | -$1,991 | $0 |
| Operating Expenses | $223,952 | $203,365 | $149,159 | $94,041 |
| Operating Income | -$55,688 | -$51,428 | -$34,844 | -$16,510 |
| % Margin | -26.6% | -27.5% | -24.6% | -17.5% |
| Other Income/Exp. Net | -$55 | $1,901 | -$7,971 | -$4,042 |
| Pre-Tax Income | -$55,743 | -$49,527 | -$42,815 | -$20,552 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$55,743 | -$49,527 | -$42,815 | -$20,552 |
| % Margin | -26.6% | -26.5% | -30.2% | -21.8% |
| EPS | -0.9 | -0.81 | -0.77 | -0.38 |
| % Growth | -11.1% | -5.2% | -102.6% | – |
| EPS Diluted | -0.9 | -0.81 | -0.77 | -0.38 |
| Weighted Avg Shares Out | 62,112 | 60,852 | 55,277 | 54,181 |
| Weighted Avg Shares Out Dil | 62,112 | 60,852 | 55,277 | 54,181 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4,877 | $6,726 | $1,313 | $18 |
| Interest Expense | $5,256 | $5,167 | $4,398 | $4,060 |
| Depreciation & Amortization | $8,419 | $5,352 | $2,133 | $685 |
| EBITDA | -$42,068 | -$39,008 | -$36,284 | -$15,807 |
| % Margin | -20.1% | -20.8% | -25.6% | -16.7% |